Palla Pharma Ltd
ASX:PAL
Balance Sheet
Balance Sheet Decomposition
Palla Pharma Ltd
Palla Pharma Ltd
Balance Sheet
Palla Pharma Ltd
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
1
|
4
|
2
|
2
|
1
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
4
|
2
|
2
|
1
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Short-Term Investments |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
1
|
0
|
1
|
4
|
9
|
15
|
18
|
8
|
|
| Accounts Receivables |
0
|
1
|
1
|
0
|
0
|
4
|
9
|
14
|
17
|
7
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
2
|
0
|
1
|
|
| Inventory |
4
|
6
|
5
|
0
|
8
|
7
|
16
|
19
|
22
|
27
|
|
| Other Current Assets |
2
|
2
|
4
|
3
|
1
|
1
|
4
|
3
|
1
|
2
|
|
| Total Current Assets |
7
|
11
|
11
|
3
|
11
|
13
|
34
|
39
|
43
|
37
|
|
| PP&E Net |
19
|
20
|
26
|
0
|
29
|
28
|
27
|
28
|
27
|
24
|
|
| PP&E Gross |
19
|
20
|
26
|
0
|
29
|
28
|
27
|
28
|
27
|
24
|
|
| Accumulated Depreciation |
3
|
5
|
10
|
0
|
18
|
18
|
20
|
22
|
25
|
17
|
|
| Intangible Assets |
3
|
3
|
3
|
0
|
2
|
2
|
2
|
1
|
3
|
4
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
14
|
14
|
14
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
14
|
14
|
14
|
0
|
|
| Total Assets |
29
N/A
|
33
+14%
|
40
+20%
|
0
N/A
|
42
N/A
|
43
+4%
|
77
+78%
|
84
+9%
|
90
+7%
|
67
-25%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
2
|
3
|
1
|
0
|
5
|
3
|
7
|
8
|
7
|
7
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
|
| Current Portion of Long-Term Debt |
25
|
23
|
18
|
18
|
0
|
1
|
13
|
0
|
0
|
4
|
|
| Other Current Liabilities |
2
|
0
|
1
|
0
|
1
|
0
|
2
|
2
|
2
|
2
|
|
| Total Current Liabilities |
29
|
26
|
20
|
18
|
7
|
5
|
23
|
11
|
11
|
16
|
|
| Long-Term Debt |
4
|
4
|
9
|
0
|
14
|
27
|
0
|
23
|
5
|
13
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
| Total Liabilities |
33
N/A
|
31
-8%
|
29
-6%
|
0
N/A
|
21
N/A
|
33
+56%
|
24
-27%
|
34
+46%
|
18
-47%
|
31
+72%
|
|
| Equity | |||||||||||
| Common Stock |
33
|
52
|
83
|
0
|
118
|
122
|
181
|
181
|
211
|
211
|
|
| Retained Earnings |
37
|
50
|
72
|
0
|
97
|
111
|
128
|
132
|
140
|
175
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
4
N/A
|
3
N/A
|
12
+319%
|
0
N/A
|
21
N/A
|
11
-48%
|
53
+397%
|
49
-7%
|
71
+45%
|
36
-49%
|
|
| Total Liabilities & Equity |
29
N/A
|
33
+14%
|
40
+20%
|
0
N/A
|
42
N/A
|
43
+4%
|
77
+78%
|
84
+9%
|
90
+7%
|
67
-25%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
31
|
41
|
47
|
0
|
59
|
59
|
91
|
91
|
132
|
132
|
|